Survival analysis of imatinib-resistant CML patients treated with 2G-TKI according to EVI-1 expression status. (A) OS for imatinib-resistant patients with and without detectable EVI-1 expression at the onset of 2G-TKI therapy. The probability of survival at 30 months was 95.2% for EVI-1 nonexpressors (median survival time, not reached; blue line) versus 47.5% for expressors (median survival time, 26 months; red line) (P = .0003). (B) Survival of CML patients receiving 2G-TKI therapy according to the presence of at least a MiCyR (< 95% Ph-positive metaphase) at 3 months (green line), absence of both MiCyR and EVI-1 expression at 3 months (blue line), or absence of MiCyR with presence of EVI-1 expression (red line). The graph demonstrates that, in patients who fail to achieve a MiCyR on 2G-TKI, positive EVI-1 expression is a strong predictor of poor outcome. The P values were calculated using the log-rank method.